Kura Oncology and Kyowa Kirin Forge Global Partnership to Develop and Commercialize Ziftomenib for Acute Myeloid Leukemia

Metropolis Healthcare's Landmark Study Highlights the Role of Molecular Profiling in Advancing Lung Cancer Care

Novartis Acquires Kate Therapeutics for $1.1 Billion to Advance Gene Therapies for Neuromuscular Diseases

OneCell Diagnostics Secures $16M to Revolutionize Cancer Diagnostics

FDA Grants Accelerated Approval to Ziihera® (zanidatamab-hrii) for HER2-Positive Biliary Tract Cancer

Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Home
/
update
/
details

OneCell Diagnostics Secures $16M to Revolutionize Cancer Diagnostics

NextEdge Admin

22 Nov 2024

1 min 55 sec

funding,multi-omics biomarkers,liquid biopsy

Pune-based startup OneCell Diagnostics has raised $16 million in a Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funds will support the U.S. expansion of its flagship product, OncoIndx Alfa—a cutting-edge liquid biopsy test designed to detect circulating tumor cells. This test leverages advanced technologies, including next-generation sequencing, AI/ML, bioinformatics, and multi-omics biomarkers, to deliver precise cancer diagnostics.

“We envision a future where life-saving cancer testing is accessible to all,” said Mohan Uttarwar, Co-founder and CEO. “This funding validates our vision to revolutionize personalized cancer care by integrating single-cell multi-omics analytics with liquid biopsy technology.”

Founded in 2021, OneCell operates on a B2B2C model, offering its biopsy tests through oncologists and hospitals. The company, headquartered in Mumbai, has a lab in Pune, a Silicon Valley R&D center, and employs 144 staff globally. OncoIndx Alfa aids in cancer diagnosis, treatment monitoring, disease progression tracking, and recurrence detection.

Having tested nearly 10,000 patients in India, OneCell collaborates with institutions like AIIMS, Tata Memorial Centre, Harvard Medical School, and Stanford University, aiming to redefine global cancer diagnostics with accessible and personalized solutions.